Skip to main content
SpringerLink
Log in

Cytogenetic Analysis of Patients with Hematological Malignancies

  • Published:
Cytology and Genetics Aims and scope Submit manuscript

Abstract

With this study, we aim to summarize and assess the activity and performance of the Cytogenetic sector of the Laboratory of Medical Genetics—Varna, regarding the conventional cytogenetic analysis of bone marrow samples from patients with (onco)hematological diagnoses. Another purpose is to evaluate the tendencies noticed over a period of eleven years to draw conclusions and share our experience. We have performed the analysis with the G-banding technique on 2653 samples from patients of age 0–93 yr by the current European recommendations and the International System for Human Cytogenomic Nomenclature. The greater part of these samples (90.9%) was with an indication of a hematological malignancy, most commonly Acute myeloid leukemia, Myelodysplastic syndrome, Acute lymphoid leukemia, Chronic myeloid leukemia, and Multiple myeloma. Analysis was successful in 2215 (83.5%)—from those normal karyotypes were found in 1492 (67.4%) and pathology in 723 (32.6%). Regarding the latter, the most common were complex karyotypes (30.6%), Philadelphian chromosome (21.3%), trisomy 8 (5.9%), and deletion in the long arm of chromosome 5 (4.3%). Cytogenetic analysis is a method with great impact on the evaluation of many hematological malignancies and for this reason, it remains an essential part of routine assessment of these diseases. The disadvantages of it mainly in the field of oncohematological diseases, recognized by the scientific society and confirmed in our own experience, suggest a need for an additional genetic method to overcome these limitations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.

Similar content being viewed by others

REFERENCES

  1. Avet-Loiseau, H., Attal, M., Moreau, P., et al., Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome, Blood, 2007, vol. 109, no. 8, pp. 3489–3495. https://doi.org/10.1182/blood-2006-08-040410

    Article  CAS  PubMed  Google Scholar 

  2. Ben Haj Ali, A., Amouri, A., Sayeb, M., et al., Cytogenetic and molecular diagnosis of Fanconi anemia revealed two hidden phenotypes: Disorder of sex development and cerebro-oculo-facio-skeletal syndrome, Mol. Gene-t. Genomic Med., 2019, vol.7, no. 7, p. e00694. https://doi.org/10.1002/mgg3.694

    Article  CAS  Google Scholar 

  3. Berry, N.K., Scott, R.J., Rowlings, P., et al., Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies, Crit. Rev. Oncol. Hematol., 2019, vol. 142, pp. 58–67. https://doi.org/10.1016/j.critrevonc.2019.07.016

    Article  PubMed  Google Scholar 

  4. Chalandon, Y., Barnett, M.J., Horsman, D.E., et al., Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission, Biol. Blood Marrow Transplant., 2002, vol. 8, no. 8, pp. 435–443. https://doi.org/10.1053/bbmt.2002.v8.pm12234169

    Article  PubMed  Google Scholar 

  5. Chen, Y., Cortes, J., Estrov, Z., et al., Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation, J. Clin. Oncol., 2011, vol. 28, no. 18, 2507–2513. https://doi.org/10.1200/JCO.2010.34.2873

    Article  Google Scholar 

  6. Ferguson-Smith, M.A., History and evolution of cytogenetics, Mol. Cytogenet., 2015, vol. 8, p. 19. https://doi.org/10.1186/s13039-015-0125-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Genescà, E., Morgades, M., González-Gil, C., et al., Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL), Leuk. Res., 2021, vol. 109, p. 106612. https://doi.org/10.1016/j.leukres.2021.106612

    Article  CAS  PubMed  Google Scholar 

  8. Hachmeriyan, M., Levkova, M., Stoyanova, M., et al., Standard karyotyping – a look through the European guidelines, Varna Med. Forum, 2019. https://doi.org/10.14748/vmf.v8i1.5893

  9. Heerema, N.A., Sather, H.N., Sensel, M.G., et al., Clinical significance of deletions of chromosome arm 6q in childhood acute lymphoblastic leukemia: a report from the Children’s Cancer Group, Leuk. Lymphoma, 2000, vol. 36, nos. 5–6, pp. 467–478. https://doi.org/10.3109/10428190009148394

    Article  CAS  PubMed  Google Scholar 

  10. Hemsing, A.L., Hovland, R., Tsykunova, G., et al., Trisomy 8 in acute myeloid leukemia, Expert Rev. Hematol., 2019, vol. 12, no. 11, pp. 947–958. https://doi.org/10.1080/17474086.2019.1657400

    Article  CAS  PubMed  Google Scholar 

  11. Jarošová, M., Holzerová, M., Mihál, V., et al., Complex karyotypes in childhood acute lymphoblastic leukemia: cytogenetic and molecular cytogenetic study of 21 cases, Cancer Genet. Cytogenet., 2003, vol. 145, no. 2, pp. 161–168. https://doi.org/10.1016/s0165-4608(03)00099-2

    Article  PubMed  Google Scholar 

  12. Kou, Fan, et al., Chromosome abnormalities: new insights into their clinical significance in cancer, Mol. Ther.–Oncolytics, 2020. https://doi.org/10.1016/j.omto.2020.05.010

  13. Lanneaux, J., Poidvin, A., Soole, F., et al., L’anémie de Fanconi en 2012: diagnostic, suivi pédiatrique, traitement, Arch. Pediatr., 2012, vol. 19, no. 10, pp. 1100–1109. https://doi.org/10.1016/j.arcped.2012.07.023

    Article  CAS  PubMed  Google Scholar 

  14. Lübbert, M., Wijermans, P., Kunzmann, R., et al., Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine, Br. J. Haematol., 2001, vol. 114, pp. 349–357. https://doi.org/10.1046/j.1365-2141.2001.02933.x

    Article  PubMed  Google Scholar 

  15. Marcucci, G., Mrózek, K., Ruppert, A.S., et al., Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461, J. Clin. Oncol., 2004, vol. 22, no. 12, pp. 2410–2418. https://doi.org/10.1200/JCO.2004.03.023

    Article  PubMed  Google Scholar 

  16. Mikhail, F., Heerema, N., Rao, K., et al., Section E6.1–6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow–acquired chromosomal abnormalities, Genet. Med., 2016. https://doi.org/10.1038/gim.2016.50

  17. Morris, C.M., Chronic myeloid leukemia: cytogenetic methods and applications for diagnosis and treatment, Methods Mol. Biol., 2011. https://doi.org/10.1007/978-1-61779-074-4_4

  18. Moreau, P., San Miguel, J., Sonneveld, P., et al., ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 2017, vol. 28, pp. 52–61. https://doi.org/10.1093/annonc/mdx096

    Article  Google Scholar 

  19. Pogosova-Agadjanyan, E.L., Moseley, A., Othus, M., et al., AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report, Biomarker Res., 2020, vol. 8, p. 29. https://doi.org/10.1186/s40364-020-00208-1

    Article  Google Scholar 

  20. Rack, K.A., van den Berg, E., Haferlach, C., et al., European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms, Leukemia, 2019, vol. 33, pp. 1851–1867. https://doi.org/10.1038/s41375-019-0378-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Richard, D., Hammer, M.D., Donald Doll, M.D., et al., Is it time for a new gold standard? FISH vs cytogenetics in AML diagnosis, Am. J. Clin. Pathol., 2016, vol. 145, no. 3, pp. 430–432. https://doi.org/10.1093/ajcp/aqw008

    Article  CAS  Google Scholar 

  22. Sampaio, M.M., Santos, M.L.C., Marques, H.S., et al., Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review, World J. Clin. Oncol., 2021, vol. 12, no. 2, pp. 69–94. https://doi.org/10.5306/wjco.v12.i2.69

    Article  PubMed  PubMed Central  Google Scholar 

  23. Santos, M.F.M., Oliveira, F.C.A.C., Kishimoto, R.K., et al., Pre-analytical parameters associated with unsuccessful karyotyping in myeloid neoplasm: a study of 421 samples, Braz. J. Med. Biol. Res., 2019, vol. 52, no. 2, p. e8194. https://doi.org/10.1590/1414-431X20188194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sasha, T. and Waclaw, J., Loss of complete cytogenetic response after nilotinib discontinuation, Hematol. Clin. Pract., 2020, vol. 11. https://doi.org/10.5603/Hem.2020.0016

  25. Shahjahani, M., Hadad, E.H., Azizidoost, S., et al., Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility, Oncol. Rev., 2019, vol. 13, p. 389. https://doi.org/10.4081/oncol.2019.389

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Stoyanova, M., Tsvetkova, M., Levkova, M., et al., Cytogenetic studies in children—the experience of the laboratory of medical genetics—Varna for a period of 10 years, Pediatria, 2021. ISSN 0479-7876

  27. Tang, G., Hidalgo Lopez, J.E., Wang, S.A., et al., Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera, Haematologica, 2017, vol. 102, no. 9. https://doi.org/10.3324/haematol.2017.165795

Download references

Funding

The authors did not receive support from any organization for the submitted work.

Author information

Authors and Affiliations

  1. Department of Medical genetics, Faculty of Medicine, Medical University of Varna, Varna, Bulgaria

    D. Yahya & L. Angelova

  2. Department of Internal diseases, Faculty of Medicine, Medical University of Varna, Varna, Bulgaria

    I. Micheva

  3. Laboratory of Medical genetics, UMHAT “St. Marina”, Varna, Bulgaria

    D. Yahya, V. Miteva & T. Ruseva

  4. Clinic of Hematology, UMHAT “St. Marina”, Varna, Bulgaria

    I. Micheva

Authors
  1. D. Yahya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Miteva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Micheva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Ruseva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Angelova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Yahya.

Ethics declarations

Conflict of interest. The authors declare that they have no conflicts of interest.

Statement of compliance with standards of research involving humans as subjects. This a retrospective study and as such does not require approval by the ethical committee. Still, informed consent is obtained from all individual participants included in the study since it is a part of the routine administration in the University hospital.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yahya, D., Miteva, V., Micheva, I. et al. Cytogenetic Analysis of Patients with Hematological Malignancies. Cytol. Genet. 57, 272–281 (2023). https://doi.org/10.3103/S0095452723030106

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3103/S0095452723030106

Keywords:

Search

Navigation